Will the Phase 2 trial "A Study of BGB-11417 in Participants With Myeloid Malignancies" reach primary completion on or before Feb 8, 2028?

Resolves Yes if ClinicalTrials.gov record NCT04771130 (BeOne Medicines) shows an actual primary completion date on or before Feb 8, 2028. Registered date at generation: Feb 8, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Feb 8, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.